ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy

Leung, Elaine Lai-Han*; Li, Run-Ze; Fan, Xing-Xing; Wang, Lily Yan; Wang, Yan; Jiang, Zebo; Huang, Jumin; Pan, Hu-Dan; Fan, Yue; Xu, Hongmei; Wang, Feng; Rui, Haopeng; Wong, Piu; Sumatoh, Hermi; Fehlings, Michael; Nardin, Alessandra; Gavine, Paul; Zhou, Longen; Cao, Yabing*; Liu, Liang*广东省人民医院; 广州中医药大学
Nature Communications2023-8-22DOI: 10.1038/s41467-023-40631-0
1被引6阅读
引用收藏
分享

摘要

Immune checkpoint blockade therapy improved the survival rates of non-small cell lung cancer but only a proportion of patients benefit. Here authors follow the humoral and cellular immunological parameters of patients undergoing anti-PD1 therapy longitudinally and find that levels and functional properties of cytotoxic T cells, and especially CD8(+)CD101(hi)TIM3(+) cells determine the response. @@@ Response to immunotherapy widely varies among cancer patients and identification of parameters associating with favourable outcome is of great interest. Here we show longitudinal monitoring of peripheral blood samples of non-small cell lung cancer (NSCLC) patients undergoing anti-PD1 therapy by high-dimensional cytometry by time of flight (CyTOF) and Meso Scale Discovery (MSD) multi-cytokines measurements. We find that higher proportions of circulating CD8(+) and of CD8(+)CD101(hi)TIM3(+) (CCT T) subsets significantly correlate with poor clinical response to immune therapy. Consistently, CD8(+) T cells and CCT T cell frequencies remain low in most responders during the entire multi-cycle treatment regimen; and higher killer cell lectin-like receptor subfamily G, member 1 (KLRG1) expression in CCT T cells at baseline associates with prolonged progression free survival. Upon in vitro stimulation, CCT T cells of responders produce significantly higher levels of cytokines, including IL-1 & beta;, IL-2, IL-8, IL-22 and MCP-1, than of non-responders. Overall, our results provide insights into the longitudinal immunological landscape underpinning favourable response to immune checkpoint blockade therapy in lung cancer patients.

学科与关键词

关键词
T-CELLSPD-1PEMBROLIZUMABIPILIMUMABSAMPLES
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Nature Communications
发表日期
2023-08-22
卷期
第 14 卷, 第 1 期
DOI
10.1038/s41467-023-40631-0
语言
ENGLISH
成果收录
SCIE
资助标注
Macau Science and Technology Development Fund [0063/2022/A2 001/2020/ALC]; Janssen therapeutic fund [ICD#1101175]; National Natural Science Foundation of China [82204677]; Science and Technology Projects in Guangzhou [SL2022A04J00459]; 2020 Guangdong Provincial Science and Technology Innovation Strategy Special Fund (Guangdong-Hong Kong-Macau Joint Lab) [2020B1212030006]; Start-up Research Grant of University of Macau [SRG2022-00020-FHS]; Faculty of Health Science, University of Macau; State Key Laboratory of Dampness Syndrome of Chinese Medicine [SZ2022KF20]

作者

  • L

    Leung, Elaine Lai-Han (通讯) (第一作者)

  • L

    Li, Run-Ze

    2 · guangdong prov hosp · guangzhou univ chinese med

查看全部 20 位作者收起作者
  • F

    Fan, Xing-Xing

  • W

    Wang, Lily Yan

  • W

    Wang, Yan

  • J

    Jiang, Zebo

  • H

    Huang, Jumin

  • P

    Pan, Hu-Dan

    2 · guangdong prov hosp · guangzhou univ chinese med

  • F

    Fan, Yue

  • X

    Xu, Hongmei

  • W

    Wang, Feng

  • R

    Rui, Haopeng

  • W

    Wong, Piu

  • S

    Sumatoh, Hermi

  • F

    Fehlings, Michael

  • N

    Nardin, Alessandra

  • G

    Gavine, Paul

  • Z

    Zhou, Longen

  • C

    Cao, Yabing (通讯)

  • L

    Liu, Liang (通讯)

    2 · guangdong prov hosp · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417